Soybean yield, seed quality and thresh efficiency by mechanisation at different harvesting stages and postharvest ripening

This study determined the most appropriate and earliest soybean harvesting stage and the number of days of postharvest ripening with minimal effects on seed losses and quality when mechanical harvest and threshing were applied. Harvesting stages at four physiological maturities (60, 70, 80, and 90%) and various days of postharvest ripening treatment (1, 2, and 3 days) were applied for two soybean varieties DT12 and DT26. Harvesting at physiological maturity of 90% recorded the highest seed-shattering loss but the least seed damage (<5%) and highest seed quality, followed by a physiological maturity of 80%. There were no significant differences in seed yields between harvesting stages of 80 and 90% maturity. Harvesting soybeans at a physiological maturity of 60 and 70% resulted in no seed losses but a significant reduction in seed quality. To avoid adverse weather, an early harvest stage at a physiological maturity of 80% is suggested. Although postharvest ripening of soybeans for early harvest caused seed shattering losses (2-5%), it was necessary to ensure seed quality. These results indicate effective and practical methods for farmers at small households to use in early mechanical harvesting of soybeans

Burden of diarrheal diseases from biogas wastewater exposure among smallholder farmers in Ha Nam province, Vietnam

Livestock production has developed rapidly in Vietnam in recent years, particularly at the small-scale which account for 65% of the total livestock production. Biogas systems are commonly used to treat livestock waste, however, the health risks from biogas wastewater exposure at smallholder farms are not yet well understood. A quantitative microbial risk assessment approach was applied to estimate the burden of diarrheal diseases from biogas wastewater exposure among 451 smallholder farmers using biogas systems in Ha Nam province. A total of 150 biogas wastewater samples were collected and analysed for E. coli, Giardia, and Cryptosporidium. The study showed that farmers faced diarrheal disease risks due to exposure to biogas wastewater at different exposure scenarios. The calculated annual risk of diarrheal disease by E. coli ranked from 0.15 to 0.21; by Giardia ranked from 0.022 to 0.095; and by Cryptosporidium ranked from 0.006 to 0.015. The estimated diarrheal diseases burden from pathogens in all exposure scenarios largely exceeded the reference level of health outcome target of 10-6DALYs loss per person per year recommended by WHO. The results suggest the importance in reducing concentrations of pathogens in biogas wastewater before use in the fields as a means for mitigating public health impacts

A community participatory intervention model to reduce the health risks from biogas wastewater in Hanam Province, Vietnam

In Vietnam, using biogas to treat livestock waste is common, in particular on small holder farms. However, most small holder farms do not know how to use biogas correctly and wastewater can affect health and the environment. Using a participatory approach with farmers and other stakeholders we developed and implemented a set of interventions in Hanam province to reduce health risks from biogas wastewater. Twenty-four pig farmers were selected as a "core group" to be instrumental in developing the interventions and training other farmers to correctly use biogas. The intervention model was piloted for 6 months. Several outputs were obtained including i) approval and enforcement of a "huong uoc - village law" on environmental protection; ii) training of 24 farmers from the core group in communication skills to share information on using biogas; iii) development of a 6-step program of pig cage cleaning to limit waste loaded to biogas to improve the efficiency of biogas production; iv) a health monitoring books for humans and animals for use by families in the community. The results provided evidence that applying the participatory approach can lead to improved knowledge and practices of farmer using biogas and can reduce the health risks from biogas wastewater

Type 2 inflammation in eosinophilic chronic obstructive pulmonary disease

From Wiley via Jisc Publications RouterHistory: received 2020-10-12, rev-recd 2020-10-28, accepted 2020-11-11, pub-electronic 2020-12-05, pub-print 2021-06Article version: VoRPublication status: PublishedFunder: NIHR Manchester Biomedical Research Centre; Id: http://dx.doi.org/10.13039/10001465

The influence of human genetic variation on early transcriptional responses and protective immunity following immunization with Rotarix vaccine in infants in Ho Chi Minh City in Vietnam : a study protocol for an open single-arm interventional trial [awaiting peer review]

Background: Rotavirus (RoV) remains the leading cause of acute gastroenteritis in infants and children aged under five years in both high- and low-middle-income countries (LMICs). In LMICs, RoV infections are associated with substantial mortality. Two RoV vaccines (Rotarix and Rotateq) are widely available for use in infants, both of which have been shown to be highly efficacious in Europe and North America. However, for unknown reasons, these RoV vaccines have markedly lower efficacy in LMICs. We hypothesize that poor RoV vaccine efficacy across in certain regions may be associated with genetic heritability or gene expression in the human host. Methods/design: We designed an open-label single-arm interventional trial with the Rotarix RoV vaccine to identify genetic and transcriptomic markers associated with generating a protective immune response against RoV. Overall, 1,000 infants will be recruited prior to Expanded Program on Immunization (EPI) vaccinations at two months of age and vaccinated with oral Rotarix vaccine at two and three months, after which the infants will be followed-up for diarrheal disease until 18 months of age. Blood sampling for genetics, transcriptomics, and immunological analysis will be conducted before each Rotarix vaccination, 2-3 days post-vaccination, and at each follow-up visit (i.e. 6, 12 and 18 months of age). Stool samples will be collected during each diarrheal episode to identify RoV infection. The primary outcome will be Rotarix vaccine failure events (i.e. symptomatic RoV infection despite vaccination), secondary outcomes will be antibody responses and genotypic characterization of the infection virus in Rotarix failure events. Discussion: This study will be the largest and best powered study of its kind to be conducted to date in infants, and will be critical for our understanding of RoV immunity, human genetics in the Vietnam population, and mechanisms determining RoV vaccine-mediated protection. Registration: ClinicalTrials.gov, ID: NCT03587389. Registered on 16 July 2018

Neonatal-Onset Multisystem Inflammatory Disease Responsive to Interleukin-1β Inhibition

Neonatal-onset multisystem inflammatory disease is characterized by fever, urticarial rash, aseptic meningitis, deforming arthropathy, hearing loss, and mental retardation. Many patients have mutations in the cold-induced autoinflammatory syndrome 1 (CIAS1) gene, encoding cryopyrin, a protein that regulates inflammation

Modulation of blood inflammatory markers by benralizumab in patients with eosinophilic airway diseases

Abstract Background Benralizumab, a humanized, afucosylated, monoclonal antibody that targets interleukin-5 receptor α, depletes eosinophils and basophils by enhanced antibody-dependent cell-mediated cytotoxicity. It demonstrated efficacy for patients with moderate to severe asthma and, in a Phase IIa trial, for chronic obstructive pulmonary disease (COPD) with eosinophilic inflammation. We investigated effects of benralizumab 100 mg every 8 weeks (first three doses every 4 weeks) subcutaneous on blood inflammatory markers through proteomic and gene-expression analyses collected during two Phase II studies of patients with eosinophilic asthma and eosinophilic COPD. Methods Serum samples for proteomic analysis and whole blood for gene expression analysis were collected at baseline and 52 weeks (asthma study) or 32 weeks (COPD study) post-treatment. Proteomic analyses were conducted on a custom set of 90 and 147 Rules-Based Medicine analytes for asthma and COPD, respectively. Gene expression was profiled by Affymetrix Human Genome U133 plus 2 arrays (~ 54 K probes). Gene set variation analysis (GSVA) was used to determine transcriptomic activity of immune signatures. Treatment-related differences between analytes, genes, and gene signatures were analyzed for the overall population and for patient subgroups stratified by baseline blood eosinophil count (eosinophil-high [≥300 cells/μL] and eosinophil-low [< 300 cells/μL]) via t-test and repeated measures analysis of variance. Results Eosinophil chemokines eotaxin-1 and eotaxin-2 were significantly upregulated (false discovery rate [FDR] < 0.05) by approximately 2.1- and 1.4-fold in the asthma study and by 2.3- and 1.7-fold in the COPD study following benralizumab treatment. Magnitude of upregulation of these two chemokines was greater for eosinophil-high patients than eosinophil-low patients in both studies. Benralizumab was associated with significant reductions (FDR < 0.05) in expression of genes associated with eosinophils and basophils, such as CLC, IL-5Rα, and PRSS33; immune-signaling complex genes (FCER1A); G-protein–coupled receptor genes (HRH4, ADORA3, P2RY14); and further immune-related genes (ALOX15 and OLIG2). The magnitude of downregulation of gene expression was greater for eosinophil-high than eosinophil-low patients. GSVA on immune signatures indicated significant treatment reductions (FDR < 0.05) in eosinophil-associated signatures. Conclusions Benralizumab is highly selective, modulating blood proteins or genes associated with eosinophils or basophils. Modulated protein and gene expression patterns are most prominently altered in eosinophil-high vs. eosinophil-low patients. Trial registration NCT01227278 and NCT01238861